业界动态国内医卫资讯

FDA批准Pimicotinib用于症状性TGCT

Medscape News · 2026-11-11 03:29

摘要

Serono公司表示,其CSF-1R抑制剂在3期试验中客观缓解率最高,有望成为“同类最佳”。Medscape Medical News

English
FDA Approves Pimicotinib for Symptomatic TGCT

With the highest objective response rate in a phase 3 trial, Serono says its CSF-1R inhibitor is a potential 'best-in-class.' Medscape Medical News

内容仅供参考,不构成诊疗建议,不能替代执业医师的诊断。

← 返回元界